Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma

Related Experiment Video

Updated: Jun 25, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Agatha Labrinidis1, Peter Diamond, Sally Martin

  • 1Discipline of Orthopaedics and Trauma, The University of Adelaide, Royal Adelaide Hospital, and Hanson Institute, South Australia, Australia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 12, 2009
PubMed
Abstract

Insights

Recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) effectively reduced multiple myeloma tumor burden and protected against bone destruction in a mouse model. This suggests TRAIL is a promising therapeutic for multiple myeloma patients.

Area of Science:

  • Oncology
  • Bone Biology
  • Apoptosis Signaling

Background:

  • Multiple myeloma is an incurable hematologic malignancy.
  • Therapeutic strategies are needed to combat tumor progression and bone destruction.
  • Recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential anti-cancer agent.

Purpose of the Study:

  • To investigate the efficacy of recombinant soluble Apo2L/TRAIL in inhibiting tumor progression and bone destruction in a xenogeneic multiple myeloma model.
  • To assess the impact of Apo2L/TRAIL on myeloma burden within the bone microenvironment.

Main Methods:

  • A xenogeneic mouse model of multiple myeloma was established using Apo2L/TRAIL-sensitive human myeloma cells (RPMI-8226 or KMS-11) xenografted into the tibial marrow cavity of nude mice.
  • Tumor burden was monitored using bioluminescence imaging.
  • Myeloma-induced osteolysis was quantified using in vivo micro-computed tomography.

Main Results:

  • Transplanted myeloma cells progressively increased tumor burden and caused extensive osteolysis in the bone marrow.
  • Treatment with recombinant soluble Apo2L/TRAIL significantly reduced myeloma burden in the bone marrow.
  • Apo2L/TRAIL treatment conferred significant protection against myeloma-induced osteolysis, mediated by direct apoptosis of myeloma cells.

Conclusions:

  • This study provides the first in vivo evidence of recombinant soluble Apo2L/TRAIL's efficacy against multiple myeloma burden and associated bone destruction within the bone microenvironment.
  • The findings support the direct apoptotic action of Apo2L/TRAIL on myeloma cells in vivo.
  • Recombinant soluble Apo2L/TRAIL warrants clinical evaluation for patients with multiple myeloma.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...